IP Library › Granted Patent US 6,989,378
Granted Patent B2
US 6,989,378 · App. 10/964,076 · Granted Jan 24, 2006

Testosterone derivative

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,989,378
App. No.
10/964,076
Granted
Jan 24, 2006
Kind
B2
Abstract

The invention is the novel androgen (7α,17β)-7-methyl-17-[(1-oxoundecyl)oxy]estr-4en-3one (MENT undecanoate). This compound distinguishes favourably from other testosterone derivatives in that it has a good solubility in oily media. It particularly exhibits a good dissolved potency relative to testosterone. The compound is particularly suitable for administration by means of injection.

Claims (6)

1. A kit for male contraception, comprising:

a means for the administration of a progestagen and

a means for the administration of an androgen, wherein the latter means is a pharmaceutical formulation, comprising:

(7α, 17β)-7-methyl-17-[(1-oxoundecyl)oxy]estr-4-en-3-one and

a pharmaceutically acceptable carrier.

2. The kit for male contraception according to claim 1 , wherein the pharmaceutically acceptable carrier is a liquid in which (7α, 17β)-7-methyl-17-[(1-oxoundecyl)oxy]estr4-en-3-one is dissolved.